Literature DB >> 20003889

Translational modulation of proteins expressed from bicistronic vectors.

Prasun J Mishra1, Lata G Menon, Pravin J Mishra, Philipp Mayer-Kuckuk, Joseph R Bertino, Debabrata Banerjee.   

Abstract

Bicistronic vectors are useful tools for exogenous expression of two gene products from a single promoter element; however, reduced expression of protein from the second cistron compared with the first cistron is a common limitation to this approach. To overcome this limitation, we explored use of dihydrofolate reductase (DHFR) complementary DNA encoded in bicistronic vectors to induce a second protein of interest by methotrexate (MTX) treatment. Previous studies have demonstrated that levels of DHFR protein and DHFR fusion protein can be induced translationally following MTX treatment of cells. We demonstrated that in response to MTX treatment, DHFR partner protein in a bicistronic construct is induced for longer periods of time when compared with endogenous DHFR and DHFR fusion protein, in vitro and in vivo. Using rapamycin pretreatment followed by MTX treatment, we also devised a strategy to modulate levels of two proteins expressed from a bicistronic construct in a cap-independent manner. To our knowledge, this is the first report demonstrating that levels of proteins in DHFR-based bicistronic constructs can be induced and modulated using MTX and rapamycin treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20003889      PMCID: PMC2864087     

Source DB:  PubMed          Journal:  Mol Imaging        ISSN: 1535-3508            Impact factor:   4.488


  31 in total

1.  Novel fluorescence-based screen to identify small synthetic internal ribosome entry site elements.

Authors:  A Venkatesan; A Dasgupta
Journal:  Mol Cell Biol       Date:  2001-04       Impact factor: 4.272

Review 2.  Internal ribosome entry sites in eukaryotic mRNA molecules.

Authors:  C U Hellen; P Sarnow
Journal:  Genes Dev       Date:  2001-07-01       Impact factor: 11.361

Review 3.  Myeloprotection with drug-resistance genes.

Authors:  Debabrata Banerjee; Joseph R Bertino
Journal:  Lancet Oncol       Date:  2002-03       Impact factor: 41.316

4.  Characterization and drug sensitivity of four newly established colon adenocarcinoma cell lines to antifolate inhibitors of thymidylate synthase.

Authors:  G S Longo; J Izzo; R Gorlick; D Banerjee; S C Jhanwar; J R Bertino
Journal:  Oncol Res       Date:  2001       Impact factor: 5.574

5.  Protein factor requirements of the Apaf-1 internal ribosome entry segment: roles of polypyrimidine tract binding protein and upstream of N-ras.

Authors:  S A Mitchell; E C Brown; M J Coldwell; R J Jackson; A E Willis
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

6.  Poly(A)-binding protein interaction with elF4G stimulates picornavirus IRES-dependent translation.

Authors:  Y V Svitkin; H Imataka; K Khaleghpour; A Kahvejian; H D Liebig; N Sonenberg
Journal:  RNA       Date:  2001-12       Impact factor: 4.942

7.  Composition and arrangement of genes define the strength of IRES-driven translation in bicistronic mRNAs.

Authors:  M Hennecke; M Kwissa; K Metzger; A Oumard; A Kröger; R Schirmbeck; J Reimann; H Hauser
Journal:  Nucleic Acids Res       Date:  2001-08-15       Impact factor: 16.971

8.  Functional characterization of the X-linked inhibitor of apoptosis (XIAP) internal ribosome entry site element: role of La autoantigen in XIAP translation.

Authors:  M Holcik; R G Korneluk
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

9.  A cell cycle-dependent internal ribosome entry site.

Authors:  S Pyronnet; L Pradayrol; N Sonenberg
Journal:  Mol Cell       Date:  2000-04       Impact factor: 17.970

10.  Cells exposed to antifolates show increased cellular levels of proteins fused to dihydrofolate reductase: a method to modulate gene expression.

Authors:  Philipp Mayer-Kuckuk; Debabrata Banerjee; Sundeep Malhotra; Mikhail Doubrovin; Marian Iwamoto; Tim Akhurst; Julius Balatoni; William Bornmann; Ronald Finn; Steven Larson; Yuman Fong; Juri Gelovani Tjuvajev; Ronald Blasberg; Joseph R Bertino
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

View more
  2 in total

1.  Treatment of a solid tumor using engineered drug-resistant immunocompetent cells and cytotoxic chemotherapy.

Authors:  Anindya Dasgupta; Jordan E Shields; H Trent Spencer
Journal:  Hum Gene Ther       Date:  2012-04-18       Impact factor: 5.695

2.  Modulation of immunogenicity and immunoprotection of mucosal vaccine against coxsackievirus B3 by optimizing the coadministration mode of lymphotactin adjuvant.

Authors:  Yan Yue; Wei Xu; Sidong Xiong
Journal:  DNA Cell Biol       Date:  2011-10-11       Impact factor: 3.311

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.